GENE ONLINE|News &
Opinion
Blog

AstraZeneca
AstraZeneca’s Forxiga Gets EU Nod To Treat Symptomatic Chronic Heart Failure
2023-02-08
JPM23: Acquisition Announcements From JP Morgan Healthcare Conference 2023 Day One
2023-01-10
GeneOnline’s Pick: Top 10 Industry News Stories in 2022
2022-12-26
AstraZeneca Expands Oncology Portfolio with $320 Million Neogene Acquisition
2022-11-29
Sanofi, GSK Secure European COVID-19 Booster Approval, AstraZeneca Withdraws U.S. Application
2022-11-10
AstraZeneca’s COVID-19 Vaccine Finally Wins Full Authorization in the European Union
2022-11-01
AstraZeneca’s Treatment for Rare Throat Disease, Eosinophilic esophagitis, Fails Primary Endpoint
2022-10-25
AstraZeneca’s Liver Cancer Treatment Combination Snatches FDA Approval
2022-10-24
Alexion Snaps Up LogicBio Seeking Expansion into Genomic Medicines
2022-10-03
AstraZeneca’s Rare Disease Treatment Wins Third Approval in European Union
2022-09-23
AstraZeneca Blocks Ionis’ Hypercholesterolemia Treatment from Moving into a Phase 3 Study
2022-09-23
AstraZeneca, Sanofi’s RSV Antibody Recommended For Approval In EU
2022-09-19
AstraZeneca’s Imfinzi Combination Becomes First Approved Immunotherapy Regimen For Biliary Tract Cancer
2022-09-06
AstraZeneca’s Role in COVID-19 Slows Down as World Looks to mRNA Vaccines
2022-08-31
Despite Global Acceptance, The UK Refuses to Buy AstraZeneca’s Evusheld, Citing ‘Insufficient Data’
2022-08-16
1 2 3
LATEST
OncoC4 Bags $200 Million In CTLA-4 Antibody Pact With BioNTech
2023-03-21
HHS Issues Initial Guidance on Negotiation Program as Government’s Latest Move to Reduce Drug Prices
2023-03-21
First-Ever Insect Brain Neuron Map Completed
2023-03-21
AbbVie Unveils Latest Data For Skyrizi In Difficult-To-Treat Psoriasis
2023-03-20
Sanofi Slashes Insulin Prices by Up to 78% Following Hot On the Heels of Major Competitors
2023-03-19
Novartis Snags Pediatric Brain Cancer Indication for Oncology Combination Therapy
2023-03-19
Pfizer, Astellas’ Prostate Cancer Drug Xtandi Achieves Goals In Phase 3
2023-03-19
Scroll to Top